InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Implement Board-Approved Reverse Stock Split
June 6, 2023
Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common stock, at a ratio of one-for-thirty, as unanimously […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Presents Phase 3 SAD Study Results at ASCP Annual Meeting
June 1, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has reported the results of its phase 3 open-label study of fasedienol (“PH94B”) nasal spray for the treatment of adults with social anxiety disorder (“SAD”). The company […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Report Phase 3 Study Results at Upcoming ASCP Annual Meeting
May 31, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, announced that it will be sharing the results of its phase 3 open-label study of fasedienol (“PH94B”) nasal spray for the treatment of adults with social anxiety […]
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Recognized with MHA Platinum Bell Seal for Workplace Mental Health
May 24, 2023
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has been recognized by Mental Health America (“MHA”) for its commitment to fostering mental health and well-being in the workplace. According to the announcement, the company earned […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Portfolio with New European Patent for AV-101
April 6, 2023
Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that the European Patent Office (“EPO”) has granted a patent for AV-101, Vistagen’s oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist. “Expanding our patent […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Receives Positive FDA Feedback Regarding Use of LSAS in Planned Phase 3 Study
March 30, 2023
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting positive feedback from the U.S. Food and Drug Administration (“FDA”). The feedback is in relation to the company’s use of the Liebowitz Social Anxiety Scale […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Results from PH94B Phase 3 Study
March 22, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced positive data from its phase 3 open-label study. According to the update, the study is designed to evaluate the safety and tolerability of multiple, as-needed intranasal […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Provides Update on Phase 1 Clinical Trial of Proprietary PH10
March 9, 2023
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced key updates regarding its phase 1 clinical trial of itruvone (“PH10”). The company reported that the last participant in the trial has completed the study […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Upcoming Health Care Conference
March 2, 2023
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will be presenting at the 43rd annual Cowen Health Care Conference. The three-day event is scheduled for March 6–8, 2023, in Boston. VistaGen CEO Shawn Singh will […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Secures US Patent for PH80 Nasal Spray for Treatment of Migraine
March 1, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted a U.S. patent for Vistagen’s PH80 nasal spray for the treatment of migraine. According to the […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2023 Financial Results, Corporate Update
February 8, 2023
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting on its fiscal year 2023 third quarter ended December 31, 2022; the report also included corporate highlights for the same period. According to the report, […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Q3 Fiscal 2023 Results Call and Webcast
February 6, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced that it will host a conference call and webcast at 2:00 p.m. PT/5:00 p.m. ET on Tuesday, Feb. 7, 2023. At that time, Vistagen will report […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Closing of Strategic Acquisition
February 2, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced the closing of its acquisition of Pherin Pharmaceuticals Inc., a privately held drug development company focused on neuropsychiatric and neuroendocrine conditions. Vistagen now owns all intellectual […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Doses First Participants in PH10 Phase 1 Clinical Trial
January 24, 2023
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, announced that the first cohort of healthy volunteers has been dosed in its U.S. phase 1 clinical trial of PH10. The trial includes a newly optimized formulation […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Set to Commence Antidepressant Nasal Spray Trial This Quarter
January 19, 2023
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is preparing to launch a phase 1 trial of its novel pherine nasal spray for major depressive disorder (“MDD”). The company is anticipating that the trial, which […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Completes 4-Week Treatment Protocol for Final Patient in Phase 2 AjDA Trial
January 10, 2023
Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that the last patient has completed the study protocol in its phase 2 clinical trial of PH94B for the treatment of adults experiencing […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Takes Key Steps to Protect, Enhance IP Program
January 3, 2023
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has recently filed national applications at the U.S. Patent and Trademark Office designed to provide additional patent protection for its lead product candidate, PH94B. The company has […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Plans to Acquire Pherin Pharmaceuticals Inc.
December 21, 2022
Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. Today Vistagen, together with Pherin Pharmaceuticals, a clinical-stage drug development company focused on the discovery and development of investigational pherine compounds for treatment of neuropsychiatric and neuroendocrine […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces FDA Fast Track Designation for Development of Proprietary MDD Treatment
December 6, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for the development of its proprietary investigational nasal spray: PH10. The designation can expedite […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Publishes Positive Preclinical Findings Related to AV-101
November 17, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has published findings of a preclinical study of its oral NMDA receptor glycine site antagonist, AV-101. The positive findings evaluated the effects of AV-101 in a widely […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2023 Financial Report, Corporate Update
November 11, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting its financial results and corporate highlights for fiscal year 2023, the period ended Sept. 30, 2022. Among the highlights include news that an independent analysis […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Q2 2023 Financial Results Call, Webcast
November 4, 2022
Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that it will host a conference call and webcast at 2:00 p.m. Pacific Time on Nov. 10, 2022, to report financial results for […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Stifel 2022 Healthcare Conference
November 3, 2022
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced that its Chief Executive Officer Shawn Singh will present and host one-on-one meetings at the Stifel 2022 Healthcare Conference taking place in New York on Nov. […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Virtual Roundtable on Innovative Approaches to Mental Health Treatment
October 26, 2022
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced that the company’s Chief Executive Officer, Shawn Singh, will lead a Concordia Live Webinar on the need for innovative approaches to mental health treatment. According to […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Report on 2022 Annual Meeting of Stockholders Voting, Partial Adjournment
October 20, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, is reporting on business conducted during its 2022 Annual Meeting of Stockholders. According to the announcement, the meeting was partially adjourned and will reconvene on Oct. 28, […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Shares Shareholder Voting Recommendations from Leading Proxy Advisory Firms
October 6, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, announced that two leading independent proxy advisory firms have provided voting recommendations for upcoming annual meeting of stockholders. According to the announcement, the two firms — Institutional Shareholder […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO to Participate at Cantor Neurology & Psychiatry Conference
October 3, 2022
VistaGen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company has announced that its Chief Executive Officer Shawn Singh will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming Conferences
September 9, 2022
VistaGen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced that its Chief Executive Officer Shawn Singh will participate in two upcoming investor conferences in New York. VistaGen management will also be available […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Report FY 2023 Q1 Results, Host Conference Call and Webcast
September 8, 2022
VistaGen (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced it will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET on Thursday, Aug. 11, 2022, to report financial […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2023 Financial, Corporate Report
August 12, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, is reporting its financial results for Q1 2023, or the period ended June 30, 2022. In addition, the company also released a corporate update for the company, […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Conference Call to Discuss FY 2023 Q1 Financial Results
August 9, 2022
VistaGen (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced it will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET on Thursday, Aug. 11, 2022, to report financial […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for PH94B
July 22, 2022
VistaGen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. The company today announced topline results from its PALISADE-1 phase 3 clinical trial of PH94B for the acute treatment of anxiety in adults with social anxiety disorder. […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at 2022 Concordia Americas Summit; CEO and US Surgeon General to Discuss Mental Health Crisis
July 12, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, is slated to attend the upcoming Concordia Americas Summit. The 2022 Concordia Americas Summit is scheduled for July 13–14, 2022, in Miami as well as […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at William Blair Biotech Focus Conference 2022
July 7, 2022
VistaGen (NASDAQ: VTGN) is a late clinical-stage, central nervous system (“CNS”)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company today announced that its CEO Shawn Singh will participate in a panel discussing unmet needs and novel therapies in neuropsychiatry at the William Blair […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Corporate Update, FY 2022 Results
June 24, 2022
VistaGen (NASDAQ: VTGN) is a late clinical-stage, central nervous system (“CNS”)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company today provided a corporate update and reported financial results for its fiscal year ended March 31, 2022. “Momentum from our accomplishments throughout our fiscal […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Completes PH94B PALISADE-1 Phase 3 Clinical Study for Acute Treatment of SAD
June 22, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, announced that the last patient had completed the study protocol in its PALISADE-1 phase 3 clinical study. The study evaluated the potential for VTGN’s proprietary […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Schedules Webcast to Announce FY 2022 Results
June 17, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, has scheduled a conference call and web cast to announce its fiscal year 2022 financial results. The event is slated for June 23, 2022, at […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Present Clinical Trial Abstract at ASCP Annual Meeting
June 2, 2022
VistaGen (NASDAQ: VTGN) is a late clinical-stage, central nervous system (“CNS”)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The company today announced that the clinical trial abstract for its exploratory phase 2A clinical study in adjustment disorder with anxiety (“AjDA”) for PH94B, its investigational […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Top Investor Conferences
May 27, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, will present at two upcoming conferences scheduled in June. VistaGen CEO Shawn Singh will present at both the William Blair 42nd annual Growth Stock Conference […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Names New Chief Legal Officer
May 2, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, has announced its new chief legal officer: Reid Adler. According to the announcement, Adler’s new responsibilities will include overseeing the company’s legal affairs and providing […]